Dapagliflozin energy balance in T2D
Research type
Research Study
Full title
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes
IRAS ID
147154
Contact name
John Wilding
Contact email
Sponsor organisation
University of Liverpool
Eudract number
2013-004264-60
Research summary
Type 2 diabetes (T2DM) is a chronic medical condition characterised by high blood sugar, which leads to the development of both microvascular (retinopathy, nephropathy and neuropathy) and macrovascular (ischaemic heart disease, peripheral vascular disease and stroke) complications and is a major global public health challenge. Currently a number of established treatments are available with insulin-dependent modes of action including biguanides, sulphonylureas, thiazolidenediones, glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-IV (DPP-IV) inhibitors, as well as insulin. These therapies are usually unable to halt the progression of T2DM. Obesity is a major risk factor for T2DM, and some of the existing treatments, particularly sulphonylureas, thiazolidenediones and insulin tend to increase weight gain. New therapies are therefore being developed; inhibition of reabsorption of glucose has been proposed as a novel therapeutic target, and sodium/glucose co-transporter 2 (SGLT2) inhibitors such as dapagliflozin have been developed accordingly. Clinical studies have shown that SLGT2 inhibitors are effective at lowering glucose and also lower body weight in patients with T2DM when prescribed as monotherapy or when added to other drugs and insulin. However the weight loss appears less than expected, suggesting a compensatory increase in food intake or a change in energy expenditure. Therefore, this study is designed to examine the mechanisms underlying the changes in energy balance that occur with dapagliflozin treatment, so that in the future it might be possible to develop interventions to optimize weight loss and therefore therapeutic benefit of this agent.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
14/NW/0340
Date of REC Opinion
11 Jun 2014
REC opinion
Favourable Opinion